14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $35.67 $42.91 Friday, 3rd May 2024 CLDX stock ended at $42.56. This is 4.16% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 3.80% from a day low at $41.34 to a day high of $42.91.
90 days $35.03 $53.18
52 weeks $22.11 $53.18

Historical Celldex Therapeutics prices

Date Open High Low Close Volume
Mar 30, 2023 $36.17 $36.18 $34.81 $35.58 512 617
Mar 29, 2023 $35.42 $36.12 $34.61 $35.96 400 353
Mar 28, 2023 $35.03 $35.81 $34.39 $34.78 882 958
Mar 27, 2023 $36.51 $36.77 $35.03 $35.20 495 830
Mar 24, 2023 $34.59 $36.87 $33.83 $36.56 861 942
Mar 23, 2023 $36.56 $36.56 $34.96 $35.10 1 176 276
Mar 22, 2023 $38.77 $38.77 $36.25 $36.31 1 428 729
Mar 21, 2023 $41.00 $41.56 $38.41 $39.11 1 245 757
Mar 20, 2023 $40.50 $41.80 $39.57 $41.66 653 553
Mar 17, 2023 $42.22 $42.36 $40.75 $41.84 741 305
Mar 16, 2023 $43.27 $44.26 $42.08 $42.53 502 296
Mar 15, 2023 $43.09 $44.16 $42.67 $43.75 367 210
Mar 14, 2023 $43.80 $44.75 $43.30 $44.02 630 902
Mar 13, 2023 $41.79 $43.83 $40.34 $43.16 540 478
Mar 10, 2023 $44.04 $44.18 $40.31 $41.80 888 562
Mar 09, 2023 $45.62 $46.66 $44.03 $44.20 371 928
Mar 08, 2023 $45.30 $45.97 $44.84 $45.58 236 821
Mar 07, 2023 $45.01 $46.21 $44.99 $45.06 292 223
Mar 06, 2023 $46.81 $46.98 $44.80 $45.01 273 023
Mar 03, 2023 $46.62 $46.83 $45.65 $46.78 330 019
Mar 02, 2023 $45.85 $46.72 $45.33 $46.40 321 647
Mar 01, 2023 $43.05 $47.91 $43.04 $46.43 879 157
Feb 28, 2023 $42.48 $43.84 $42.09 $42.79 448 023
Feb 27, 2023 $42.50 $45.80 $42.35 $43.05 1 897 245
Feb 24, 2023 $40.78 $41.80 $39.96 $40.12 385 772
Click to get the best stock tips daily for free!

About Celldex Therapeutics

Celldex Therapeutics Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity... CLDX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT